subject inclusion question in replicate design for ANVISA [RSABE / ABEL]

posted by Shuanghe  – Spain, 2019-09-05 16:38 (2127 d 11:17 ago) – Posting: # 20544
Views: 3,686

Hi Helmut,

❝ ❝ […] the client's statistical consultant commented that only subjects who complete all 4 period (2T+2R) should be included, otherwise, they should be excluded even if they completed 3 period.


❝ IMHO, this doesn’t make sense. See the example in the vignette of replicateBE.


Thanks. That's my thought too so I insisted that the statistical section should be kept unchanged. Hopefully ANVISA will issue their own guideline soon...

All the best,
Shuanghe

Complete thread:

UA Flag
Activity
 Admin contact
23,425 posts in 4,928 threads, 1,682 registered users;
34 visitors (0 registered, 34 guests [including 15 identified bots]).
Forum time: 03:55 CEST (Europe/Vienna)

You can do one of two things; just shut up,
which is something I don’t find easy,
or learn an awful lot very fast,
which is what I tried to do.    Jane Fonda

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5